TY  - JOUR
AU  - Rusthoven, Chad G
AU  - Staley, Alyse W
AU  - Gao, Dexiang
AU  - Yomo, Shoji
AU  - Bernhardt, Denise
AU  - Wandrey, Narine
AU  - El Shafie, Rami
AU  - Kraemer, Anna
AU  - Padilla, Oscar
AU  - Chiang, Veronica
AU  - Faramand, Andrew M
AU  - Palmer, Joshua D
AU  - Zacharia, Brad E
AU  - Wegner, Rodney E
AU  - Hattangadi-Gluth, Jona A
AU  - Levy, Antonin
AU  - Bernstein, Kenneth
AU  - Mathieu, David
AU  - Cagney, Daniel N
AU  - Chan, Michael D
AU  - Grills, Inga S
AU  - Braunstein, Steve
AU  - Lee, Cheng-Chia
AU  - Sheehan, Jason P
AU  - Kluwe, Christien
AU  - Patel, Samir
AU  - Halasz, Lia M
AU  - Andratschke, Nicolaus
AU  - Deibert, Christopher P
AU  - Verma, Vivek
AU  - Trifiletti, Daniel M
AU  - Cifarelli, Christopher P
AU  - Debus, Jürgen
AU  - Combs, Stephanie E
AU  - Sato, Yasunori
AU  - Higuchi, Yoshinori
AU  - Aoyagi, Kyoko
AU  - Brown, Paul D
AU  - Alami, Vida
AU  - Niranjan, Ajay
AU  - Lunsford, L Dade
AU  - Kondziolka, Douglas
AU  - Camidge, D Ross
AU  - Kavanagh, Brian D
AU  - Robin, Tyler P
AU  - Serizawa, Toru
AU  - Yamamoto, Masaaki
TI  - Comparison of First-Line Radiosurgery for Small-Cell and Non-Small Cell Lung Cancer Brain Metastases (Cross-FIRE).
JO  - Journal of the National Cancer Institute
VL  - 115
IS  - 8
SN  - 0027-8874
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2023-00885
SP  - 926-936
PY  - 2023
N1  - 2023 Aug 8;115(8):926-936
AB  - Historical reservations regarding radiosurgery (SRS) for small-cell-lung-cancer (SCLC) brain metastases (BrM) include concerns for short-interval/diffuse CNS-progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small-cell-lung-cancer (NSCLC) where SRS is well established.Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000-2022 were retrospectively collected (N=892-SCLC/N=4,785-NSCLC). Data from the prospective JLGK0901 SRS trial were analyzed as a comparison cohort (N=98-SCLC/N=794-NSCLC). OS and CNS-progression were analyzed using Cox-Proportional-Hazard and Fine-Gray models, respectively, with multivariable (MV) adjustment (including age/sex/performance-status/year/extracranial disease/BrM-number/BrM-volume). Mutation-stratified analyses were performed in propensity score-matched (PSM) retrospective cohorts of EGFR/ALK-positive-NSCLC, mutation-negative-NSCLC, and SCLC.OS was superior with NSCLC over SCLC in the retrospective dataset (median-OS, 10.5 vs 8.6 months, MV-p<0.001) and JLGK0901. Hazard estimates for first CNS-progression favoring NSCLC were similar in both datasets but reached significance in the retrospective dataset only (MV-HR:0.82 [95
KW  - brain metastases (Other)
KW  - non-small cell lung cancer (NSCLC) (Other)
KW  - small-cell lung cancer (SCLC) (Other)
KW  - stereotactic radiosurgery (SRS) (Other)
KW  - whole brain radiation therapy (WBRT) (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37142267
DO  - DOI:10.1093/jnci/djad073
UR  - https://inrepo02.dkfz.de/record/275797
ER  -